Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (161-170 of 284) with videos related to

Pageof 29
Sort By:
The Oncologist|December 18, 2020
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based AnalysisFilippo Pietrantonio, Giovanni Fucà, Daniele Rossini, et al.
BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Plos One|January 17, 2023
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analysesAlberto D'Angelo, Huseyin Kilili, Robert Chapman, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trialsKenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trialsMartin D Berger, Shinichi Yamauchi, Shu Cao, et al.
The Pharmacogenomics Journal|June 22, 2018
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
The Oncologist|October 9, 2015
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New HopeFilippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, et al.
Pageof 29

Showing results (161-170 of 284) with videos related to

Sort By:
Pageof 29
The Oncologist|December 18, 2020
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based AnalysisFilippo Pietrantonio, Giovanni Fucà, Daniele Rossini, et al.
BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Plos One|January 17, 2023
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analysesAlberto D'Angelo, Huseyin Kilili, Robert Chapman, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trialsKenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trialsMartin D Berger, Shinichi Yamauchi, Shu Cao, et al.
The Pharmacogenomics Journal|June 22, 2018
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
The Oncologist|October 9, 2015
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New HopeFilippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, et al.
Pageof 29